Harmony Biosciences Holdings
Held by 1 superinvestor (HRMY).
Educational data only — not investment advice. 13F positions are self-reported and can lag up to 45 days.
Valuation
Valuation · two methods
Earnings Power & Asset Floor
Two intrinsic-value methods and a tangible asset floor — deterministic, not price forecasts or recommendations.
Harmony Biosciences Holdings (HRMY): Two methods value the business — a conservative owner-earnings DCF and a growth-credited Greenwald estimate, $24–$107 / sh. Today’s price sits inside both (price $37 as of 2026-07-02).
Model cautions
- The DCF result diverges from a zero-growth sanity check (over 50%).
- The two methods’ midpoints differ materially — growth assumptions warrant review (over 20%).
- Growth nearly matches the discount rate — the estimate is sensitive to assumptions.
An observation from two valuation methods — not investment advice, not a buy/sell signal, and not a price target.
Price as of 2026-07-02 · yahoo · DGS10 4.5% @ 2026-07-01.
Method & numbers
Owner-earnings DCF $23.86 – $42.46 · Greenwald $70.82 – $106.86 (neutral $88.27) · zero-growth base $48.81 · reproduction $19.94
Moat Franchise (moat) · terminal value 43% of present value · owner-earnings yield 6% vs 10Y 4.5%.
Graham earnings-power value (normalized NOPAT)$41.76 – $48.81 / sh
Normalized NOPAT = average operating margin over the years shown × latest-year revenue × (1 − normalized tax); then + D&A − maintenance capex (write A). Unlevered (pre-interest, attributable to all capital). Capitalized at the 9–11% rate band (read as a WACC proxy). Enterprise → equity bridge applied: + cash − total debt.
Years: 2025, 2024, 2023, 2022, 2021
v1 simplifications: Maintenance capex unavailable → degraded to the v1 simplification (maintenance capex = D&A, so the depreciation add-back nets to zero). Share-based compensation is left as a real expense (not added back). Operating margin is below its multi-year average (cyclical/declining): normalized margin capped at the latest year — no peak-margin capitalization (audit #2).
Buffett owner-earnings value$20.21 – $24.70 / sh
Owner earnings = average net income + average D&A − maintenance capex (zero-growth floor; no ΔNWC). Levered (starts from net income, already after interest — an equity-holder stream). Capitalized at the 9–11% rate band (read as a cost-of-equity proxy). No enterprise→equity bridge: the capitalized result is already equity value (subtracting debt would double-count interest).
Years: 2025, 2024, 2023, 2022, 2021
v1 simplifications: Owner earnings = net income + D&A − maintenance capex (degraded); the working-capital change is excluded (maintenance ΔNWC ≈ 0; growth ΔNWC is carried in growth value, not double-counted). One-time items are not separately normalized (multi-year averaging smooths them partially). Share-based compensation is left as a real expense (not added back); see the SBC/OE disclosure. Capitalized at the same 9–11% band as a cost-of-equity proxy (theoretically the cost of equity is higher; v2 simplification, v3 to refine).
Reproduction value = tangible net assets $780.80M + capitalized R&D $386.32M（FY 2025, 2024, 2023, 2022, 2021） = $19.94 / sh. Reproduction value = tangible net assets (equity − goodwill − intangibles) + capitalized R&D (5y straight-line), ÷ diluted shares.
Moat reading: Franchise test compares earnings power (EPV) against reproduction value (tangible net assets + capitalized R&D). EPV well above reproduction value signals a moat; near it, a commodity; below it, value destruction. A directional reading, not a verdict.
Growth value: if the moat holds for 10 yr at ROIIC ≈ 209%, $22.01–$58.05 / sh (neutral $39.46). Conservative, not a forecast.
Window FY 2025, 2024, 2023, 2022, 2021 · discount band 9%–11% · normalized tax 2% (Average effective tax rate over 5 year(s), capped at the statutory 21%.) · diluted shares.
Owner-earnings DCF: growth g₁ 10% · OE FY 2025, 2024, 2023, 2022, 2021 · Discount band: 8.98%–12.00% (DGS10 +4.5% to a 12% strict end, as of 2026-07-01). No enterprise→equity bridge: owner earnings already flow to shareholders (post-interest), so no net cash is added and no debt subtracted — matching the engine owner-earnings lamp. Two-method midpoint gap 85%.
Ownership · 13F consensus
Who's buying it
Institutional ownership aggregated across funds — consensus strength and this quarter's moves. Describes actions, not advice.
1 superinvestor hold it · $7.0M combined
Largest holder Ray Dalio
Held by 1 superinvestor of Harmony Biosciences Holdings (HRMY); this quarter 1 added (as of 2026-03-31).
13F positions are self-reported and can lag up to 45 days. Informational only — not investment advice.
Next · is it cheap
Want to see which stocks look cheap against a conservative value band?
Browse all valued stocks, ranked by value bandSuperinvestors Holding This Security
- Value$7.0MWeight (prev→now)0.0% → 0.0% ▲
Ownership overview
Harmony Biosciences Holdings (HRMY) is held by 1 of the superinvestors tracked on Compounder, with a combined $7.0M in reported 13F value. The largest position belongs to Ray Dalio, where it makes up 0.0% of the portfolio.
Over the latest quarter, 0 of the tracked filers opened a new position in HRMY, 1 added to existing ones, 0 trimmed, and 0 sold out entirely.
Holder counts and values reflect the most recent SEC Form 13F filings, through the quarter ended 2026-03-31. Source: SEC EDGAR. A 13F shows only long US-listed positions and can lag the real portfolio by up to 45 days, so this is disclosed long ownership, not a complete picture.
Holders over time
Superinvestors holding this security over the last 3 quarters: 1 → 1.
Early quarters may understate holder counts due to data backfill — read the slope with care.
Sources· SEC EDGAR 13F as of 2026-03-31 · filed 2026-05-15
Related
Stay Updated
Curated 13F moves and valuation insights, straight to your inbox.